An article about the risks of metal-on-metal hip replacement surgeries was earlier featured on the New York Times. Titled, “Remedy Is Elusive as Metallic Hips Fail at Fast Rate,” the article explains how all-metal hip replacements produce metal debris that might damage tissues around the hip bone.
The signs of a defective hip implant are swelling, pain bearing weight, pain when rising from a seated position,pain while walking, pain on the thigh or groin area, and pain on the hip area. According to statements from experts, those who have hip replacements may suffer from implant failure, metallosis, tissue damage, bone loss as well as other hip replacement problems.
Specifically, in the case of Johnson & Johnson, there are around 93,000 recipients of the ASR XL Acetabular System and the ASR Hip Resurfacing System globally.. Legal observers say that the DePuy hip replacement recall should be an example to other manufacturing companies to ensure safety of their products.According to legal observers, the DePuy hip replacement recall should stand as a lesson to other prosthesis manufacturers for the need to strengthen and certify the safety of their products.
In behalf of patients who had hip replacement implants, law firms in the US, UK and Australia have currently initiated court action against DePuy Orthopaedics, Inc. DePuy is a subsidiary company of Johnson and Johnson, which issued a worldwide recall of their products. With the number of litigation increasing worldwide, DePuy should properly handle the the hip replacement problems exerienced by its patients.
The controversial DePuy hip replacement recall was so noteworthy that three U.S. senators intended a new bill regarding the strengthening of medical device regulations. This was published last December 14, 2011 on the New York Times. The three senators were Charles E. Grassley (R-IA), Richard Blumenthal (D-CT) and Herb Kohl (D-WI). According to the Times, “these lawmakers have proposed a wave of medical device industry-friendly bills that would further streamline FDA regulations, allowing more product clearances.”
“There is clearly a need for scrutiny once products are implanted or used on patients,” stated Senator Blumenthal. This synchronized effort from a diverse group of senators demonstrates that policymakers are listening to patients, companies, and consumers about their concerns on the potential negative consequences from indulgent rules on medical device. According to legal observers, this move also demonstrates that the policymakers are acknowledging the significance of improving health care for the citizens.
For more news about personal injuries visit Personal Injury Lawsuits .